Vancouver, British Columbia (FSCwire) - Thursday, March 23, 2017 – EVITRADE Health Systems Corp. (CSE:EVA, OTCQB: AXHLF) (the “Company”) is pleased to announce that it has come to a meeting of the minds to finalize the definitive agreements with Dr. Avram Adizes and his group or syndicate for both the Voice of Heart electronic health - medical platform, and the intellectual property for cannabis oils purification and the operation and acquisition of the license of the 50 Hectare cannabis farm for the C&C Cosmeceuticals Corp. subsidiary.  The initial two Memorandum of Understanding (MOU) Letter Agreements were initially announced via press release on November 16^th, 2016.

The acquisition of the intellectual properties involves the issuance an additional 3,500,000 shares at a deemed value of $1.50. In addition 500,000 shares are to be issued for a service provider under the terms of the engagement; all issuances are subject to Canadian securities regulations, exchange and any other necessary approvals and regulations.

Also, for clarification the first divestiture for the TULIP™ IP spinout was announced correctly by the CSE Bulletin for Trading Ex-Distribution Date for Monday, March 20^th, 2017 and Record Date for Holders of Record for Settlement as of Wednesday March 22^nd, 2017.  As voted for and approved by all shareholders at the Annual General and Special Meeting, the Record Dates for each of the subsidiary company shares distribution is subject to change and any final date is to be determined by management.

For Further Information, Contact: Ron Ozols, Director

EVITRADE Health Systems Corporation

(formerly Auxellence Health Corporation)

Twitter: @evitradehealth or https://twitter.com/evitradehealth

Email: info@auxellence.com

Website: http://www.auxellence.com

CSE Micro-site: http://thecse.com/en/listings/technology/evitrade-health-systems-corp

US OTC Markets: http://www.otcmarkets.com/stock/AXHLF/news

About EVITRADE Health (CSE: EVA, OTCQB: AXHLF)

EVITRADE (formerly Auxellence Health Corp.), was founded in 2013 to provide online “digital healthcare” services for resolving common health problems. The current markets are weight-loss, high blood pressure, high blood glucose and heart arrhythmia.

About TULIP™

The TULIP™ system is an online self-service intended for adults interested in normalizing blood pressure, heart rate and rhythm, blood glucose, and body weight. Measurement procedures, conditioning protocols, and session schedules are prescribed automatically from data acquired by the user’s TULIP™ device – a blood pressure monitor with interactive protocols that can feed medical records and expert systems useful in testing, tracking and treating common health conditions.

The Tulip™ medical device has received Health Canada and CE Mark certifications.

About C&C Cosmeceuticals Corp. (“C&C” a wholly owned subsidiary of the Company)

C&C was founded in 2011 to develop, manufacture and market nutraceutical and cosmeceutical personal healthcare products and services.  It was the predecessor company that acquired Auxellence Health Corporation, which is now named EVITRADE Health Systems Corp. and is a wholly owned subsidiary. On November 15, 2016, the company announced that it signed an MOU to acquire a 50 Hectare Cannabis Farm for C&C and on January 23, 2017 the company that it signed a LOI to acquire a Plant Oils Extraction firm for C&C.  On March 3, 2017 at the shareholders meeting, C&C was voted 100% in favour of to be spun off from the parent company and it was announced on March 6, 2017 that C&C was to be spun off on a 1:1 basis.  All shareholders holding shares in EVITRADE will receive shares an equal number of shares in C&C as of the record date, which shall be announced shortly.

Disclaimers – Forward Looking Statements

This news release contains forward-looking statements based on assumptions and judgments of management regarding future events or results. Such statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward looking statements. The company disclaims any intention or obligation to revise or update such statements. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company’s Management’s Discussion and Analysis and other disclosure filings with Canadian securities regulators and on the OTC Markets website which is posted on www.sedar.com, http://thecse.com/en/listings/technology/evitrade-health-systems-corp, and http://www.otcmarkets.com/stock/AXHLF/filings. This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither the Canadian Securities Exchange (CSE or CNSX Markets), nor its Regulation Services Provider (as that term is defined in policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities law and may not be offered or sold in the “United States”, as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements is available.

To follow EVITRADE Health Systems Corp. on your favorite social media platform or financial websites, please click on the icons below.

Maximum News Dissemination by FSCwire. http://www.fscwire.com

Copyright © 2017 Filing Services Canada Inc.